Ova Peptides

Ranked #105,364 in Healthy Living, #1,062,021 overall

Ova Peptides

Definition
OVA Peptide is a class I (Kb)-restricted peptide epitope of ovalbumin presented by the class I MHC (major histocompatibility complex) molecule, H-2Kb (class I genes of the mouse MHC).

Discovery
Several ovalbumin (OVA) peptides have been used for studies of IgE response, CD4 T cells response, immediate cutaneous hypersensitivity and airways responsiveness (AR). Renz H et al.,in 1993 have analyzed the effects of sensitization of BALB/c mice to the OVA peptide amino acids 323-339, on the development of an IgE response. Daily aerosolization of OVA 323-339 for 20 min over a period of 10 days was as effective in the stimulation of a serum anti-OVA IgE antibody response as sensitization to native OVA by the same route 1. Ingulli E et al., in 1997 used confocal microscopy to track the in vivo location of fluorescent dye-labeled DC and naive TCR transgenic CD4 T cells specific for an OVA peptide-I-Ad complex after adoptive transfer into syngeneic recipients 2.

Structural Characteristics
Ovalbumin is 43 kDa protein. OVA peptides (257 - 264), H - Ser - Ile - Ile - Asn - Phe - Glu - Lys - Leu - OH, is a class I (Kb)-restricted peptide epitope of OVA, an octameric peptide from ovalbumin presented by the class I MHC molecule, H-2Kb 3. OVA (323 - 339) peptide sequence is H - Ile - Ser - Gln - Ala - Val - His - Ala - Ala - His - Ala - Glu - Ile - Asn - Glu - Ala - Gly - Arg - OH, An H-2b-restricted OVA class II epitope 4.

Mode of Action
Proteins of the class II MHC bind antigenic peptides that are subsequently presented to T cells. Most of the residues required for binding of the chicken ovalbumin (Ova) 323-339 peptide to the I-A(d) MHC class II protein are contained within the shorter 325-336 peptide. Two Ova peptides, Ova(323-335) and Ova(325-336), were found to dissociate from I-A(d) with distinct kinetics. The dissociation rates for both peptides were enhanced when the His81 residue of the MHC beta-chain was replaced with an asparagine. In the structure the betaH81 residue forms a hydrogen bond to the backbone carbonyl of I323. If the Ova(325-336) peptide were also bound in the register, there would be no comparable hydrogen-bond acceptor for the betaH81 side chain that could explain this peptide's sensitivity to the betaH81 replacement. The Ova(323-335) peptide that binds in the register does not stimulate a T-cell hybridoma that is stimulated by Ova(325-336) bound in the alternate register. These results demonstrate that a single peptide can bind to an MHC peptide in alternate registers producing distinct T-cell responses 5. Lymphoid dendritic cells (DC) are thought to play an essential role in T cell activation, the initial physical interaction between antigen-bearing DC. DC that were not exposed to the OVA peptide, homed to the paracortical regions of the lymph nodes but did not interact with the OVA peptide-specific T cells. In contrast, the OVA peptide-specific T cells formed large clusters around paracortical DC that were pulsed in vitro with the OVA peptide before injection. Interactions were also observed between paracortical DC of the recipient and OVA peptide-specific T cells after administration of intact OVA. Injection of OVA peptide-pulsed DC caused the specific T cells to produce IL-2 in vivo, proliferate, and differentiate into effector cells capable of causing a delayed-type hypersensitivity reaction. By 48 h after injection, OVA peptide-pulsed, but not unpulsed DC disappeared from the lymph nodes of mice that contained the transferred TCR transgenic population. These results demonstrate that antigen-bearing DC directly interact with naive antigen-specific T cells within the T cell-rich regions of lymph nodes. This interaction results in T cell activation and disappearance of the DC 2.

Functions
Effects of sensitization of BALB/c mice to the OVA peptide amino acids 323-339, on the development of an IgE response, immediate cutaneous hypersensitivity and airways responsiveness (AR) were analysed. Data indicates that OVA peptide 323-339 represents a T and B cell epitope of OVA, which is important in the generation and development of immediate hypersensitivity responses in BALB/c mice 1.

OVA - BIP Hybrid Peptide, This is a hybrid peptide containing OVA-Bip motif that binds to the Heat Shock Proteins (HSP 70) through the Bip sequence. Heat shock proteins derived from tumors or virally infected cells can stimulate antigen-specific CD8 T cell responses in-vitro and in-vivo. The binding motif of HSP 70 consists of a hydrophobic core of four to five amino acids and two flanking regions enriched in basic residues 6.

Cowpox virus (CPXV), a close relative of the deadly variola virus causing smallpox, is primarily a lung pathogen and is known to transmit through aerosols. CPXV suppresses dendritic cell function in vitro and leaves them unable to stimulate T cells. OVA323-339 peptide was used as second antigen and shown that a lethal CPXV infection reduces DO11.10 T cell proliferation in the lung-associated lymph node (LALN), while proliferation can still occur during a sublethal infection 7.

References
1. Renz H, Bradley K, Larsen GL, McCall C, Gelfand EW, (1993). Comparison of the allergenicity of ovalbumin and ovalbumin peptide 323- 339. Differential expansion of V beta-expressing T cell populations. The Journal of Immunology,
2. Ingulli E, Mondino A, Khoruts A, Jenkins MK (1997). In Vivo Detection of Dendritic Cell Antigen Presentation to CD4 T Cells. The Journal of Experimental Medicine.,
3. Honma K, Kohno Y, Saito K, Shimojo N, Horiuchi T, Hayashi H, Suzuki N, Hosoya T, Tsunoo H, Niimi H (2007). Allergenic epitopes of ovalbumin (OVA) in patients with hen's egg allergy: inhibition of basophil histamine release by haptenic ovalbumin peptide. Clin. Exp. Immunol., 103(3):446-453.
4. Oran A, Robinson H (2003). DNA vaccines, combining form of antigen and method of delivery to raise a spectrum of IFN-gamma and IL-4-producing CD4 and CD8 T cells. J. Immunol. ,< 1999-2005.>
5. McFarland BJ, Sant AJ, Lybrand TP, Beeson C (1999). Ovalbumin(323-339) peptide binds to the major histocompatibility complex class II I-A(d) protein using two functionally distinct registers. Biochemistry,
6. Castellino F, Boucher PE, Eichelberg K, Mayhew M, Rothman JE, Houghton AN, Germain RN (2000). Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J. Exp. Med., 191(11):1957-1964.
7. Hrusch CL, Lipsomb M, Wilder J, Lyons R (2009). Cowpox immunomodulation of a pulmonary immune response to OVA-peptide. The FASEB journal,

For more detail please visit here Ova Peptides

BIO-SYNTHESIS

BIO-SYNTHESIS, INC., is a leading life science products company with over 20 years of experience in the design and synthesis of Custom Peptide, small molecules and reagents for small scale research and bulk pharmaceutical trials. Using state of the art technology in our well-equipped laboratories.

Please visit our Blog on Blogspot Bio-Synthesis
Loading

New Amazon

Loading

New Flickr Photos

Loading

New YouTube vids

Loading

New Guestbook

New Amazon Voting (Plexo)

Please add at least one item before saving.

About BSI

"The use of state-of-the art technology has allowed Bio-Synthesis, Inc. to rapidly gain recognition for its manufacturing quality & dependability of delivery."

Founded in 1984, Bio-Synthesis, Inc. was first known as OCS Laboratories. It was the first producer of commercially available synthetic DNA and, in 1985, became a producer of synthetic peptides. In 1989, OCS incorporated as Bio-Synthesis, Inc. and moved its laboratories to Lewisville, Texas. Today, BSI occupies 10,000 square feet of modern laboratory space (completed in 1995) located 20 miles from downtown Dallas and 10 miles from D/FW airport. Among the surrounding academic institutions are: University of Texas Southwestern Medical School (12 miles), University of North Texas (10 miles), and University of North Texas Health Science Center (25 miles). These universities provide excellent library resources. Since its inception, BSI has steadily expanded its product lines and services to meet the growing needs of the molecular biology community. It has maintained its position as an aggressive, innovative company in a highly competitive marketplace without sacrificing quality. In the beginning, our primary emphasis was on synthesizing high quality DNA primers and linkers, which were the initial uses of oligos. Today, newer technologies, such as gene construction, PCR, mutagenesis, combinatorial libraries, dye/adduct labeling, DNA microarrays, peptide-nucleic acid chimeras, etc. have challenged the molecular biology field. In response, BSI has branched into several related areas including DNA paternity testing, DNA HLA typing, PNA synthesis, genomic sequencing, fluorescence-based genotyping, custom organic synthesis and other molecular biology based applications.

The Research and Development Division comprises a number of Ph.D. and M.D. professionals with backgrounds in molecular biology, immunology, nucleic acids, peptide synthesis, general organic chemistry, and automated amino acid sequencing. The Molecular Biology Division is set up to handle most modern experimental procedures; the Immunology Division specializes in immunodiagnostic-based reagents.

Not only has BSI continued to provide quality DNA products and services for the research community, but it has also become a world leader in providing custom peptide products and services. Using state-of-the-art solid phase peptide chemistries, BSI provides high quality custom peptides, performs carrier conjugations, antipeptide antibody production, antigenic peptide design, synthesis of long and/or modified peptides, MALDI TOF analysis, contract research, consultation services and more.

Biomedical researchers worldwide in universities, biotech companies, private clinics, and government agencies use products from Bio-Synthesis, Inc. in studies ranging from PCR diagnostics to cancer research and the Human Genome Project. Contact us to discover how BSI can customize products/services to suit your research requirements.

For more detail please visit our About Us

Please Contact Us :

Address: 612 E. Main street
City: Lewisville
State: Texas
Country: USA
Postal Code: 75057
Phone Number: 972-420-8505
Loading

New My Lenses

Loading

BIO-SYNTHESIS

BIO-SYNTHESIS, INC., is a leading life science products company with over 20 years of experience in the design and synthesis of Custom Peptide, small molecules and reagents for small scale research and bulk pharmaceutical trials. Using state of the art technology in our well-equipped laboratories.

Please visit our Blog on Blogspot Bio-Synthesis
Loading

Custom Antibody

As a leading supplier of genomic and proteomic research products, BSI is able to offer its customers integrated solutions for custom DNA synthesis, custom RNA synthesis, custom polyclonal antibody production, custom peptide synthesis, molecular diagnostic detection kits, DNA Real-Time PCR products, DNA microarray services and a wide range of custom DNA-based diagnostic kits and consumables.

The proteomic division is experienced in the design of peptides, both for antibody production and bioactive peptide synthesis, e.g cosmetic peptides. While the custom peptide synthesis division has the ability to produce thousands of modified or non-modified peptides per day for research applications, BSI also provides diagnostic/therapeutic GMP custom peptide production. Synthesis of custom peptides results in quantities ranging from milligrams to multi-kilograms. The staff in the custom antibody division provide expert support in the selection of peptide antigens for target antibody production and offer convenient custom-bundled packages with a wide range of host animals. In addition, peptide, antibody and protein arrays are also amongst its expertise.

BSI is a U.S. based company whose primary emphasis is on the synthesis of high quality custom products for a variety of applications and a full-service contract manufacturing organization (CMO) delivering research, development and production services for cGMP clinical batch manufacturing.

Feeling creative? Create a Lens!